Business NewsEducationEventsNewsPhysiciansResearchers

VIETHsymposium: INTACT VASCULAR EVENTS

Intact Vascular Inc., a private medical device company committed to developing solutions for minimally invasive peripheral vascular procedures, has announced the schedule of key presentations to be featured during a lunch symposium co-sponsored with Philips at the 45th annual VEITHsymposium in New York City on Thursday, Nov.15. Following the symposium, an update on the company’s TOBA II pivotal trial will be presented.

Intact Vascular’s Tack Endovascular System, a first-of-its-kind dissection repair device, is designed to preserve vessel integrity and enhance blood flow following balloon angioplasty. Patients with peripheral arterial disease who are treated with balloon angioplasty often suffer from dissections or tears that are frequently overlooked, undiagnosed and untreated.

These dissections can compromise clinical outcomes, resulting in acute thrombosis and arterial occlusions, leading to lower long-term patency rates and repeat procedures. Research has shown that intravascular ultrasound (IVUS) helps to visualize these dissections, confirming their presence and severity, often not visualized on traditional angiography1.

“The clinical impact of post-angioplasty dissections, although often under-diagnosed and under-estimated, is in fact substantial and can lead to high rates of restenosis and re-intervention,” said Bruce Shook, president and CEO of Intact Vascular.

“Our symposium highlights the importance of IVUS to assist in the diagnosis of dissections and the clinical significance of the Tack Endovascular System to minimize further complications and improve the frequently painful, debilitating symptoms for these patients.”

The co-sponsored lunch symposium, “Leave No Dissection Behind; Improve What You See, Repair with Precision”, will be held from 12:30-1:30 p.m. in the Gramercy Suite West, New York Hilton Midtown and will include the following presentations:

  • Dissections matter and they matter even more in the DCB era: Evidence above and below the knee – presented by Ehrin Armstrong, MD
  • iDissection: using IVUS to see what we are missing: iDissection classification system using intravascular imaging – presented by Nicolas Shammas, MD
  • Tack optimized angioplasty: results from TOBA II: Twelve-month pivotal trial results – presented by William Gray, MD
  • Precision dissection repair: European experience with the Tack Endovascular System – presented by Michael Lichtenberg, MD

Following the lunch symposium, Marianne Brodmann, MD from the Medical University of Graz in Austria, will present Update on the Value of Tack Assisted Balloon Angioplasty: Results of the TOBA II Study: Do the Tacks Improve PTA Patency In The Femoropopliteal Segment? from 2:40-2:45 p.m. in the Grand Ballroom West, 3rd Floor.

The Tack Endovascular System will be on display at Intact Vascular’s exhibitor booth, #215.

The Tack Endovascular System is designed to improve peripheral balloon angioplasty results in the treatment of peripheral arterial disease. Pre-loaded with six self-expanding nitinol devices for above-the-knee (ATK) interventions, the Tack Endovascular System can be deployed to treat multiple dissections using a single catheter and leaving behind >70 percent less metal than stents2. Additionally, the Tack Endovascular System offers low radial force, designed to promote healing, improve outcomes and preserve future treatment options for PAD and critical limb ischemia patients.

Intact Vascular is sponsoring three clinical trials to evaluate its Tack Endovascular System: TOBA II, TOBA II BTK and TOBA III. TOBA II is investigating the combination of the Tack implant with plain angioplasty balloons and the BARD Lutonix drug-coated balloon (DCB) in arteries above the knee. TOBA II BTK is investigating the combination of the Tack implant with plain balloon angioplasty in the arteries below the knee and is actively enrolling patients. TOBA III has completed enrollment in Europe and is investigating the combination of the Tack implant with the Medtronic IN.PACT Admiral (DCB), inclusive of long lesions. VTN

See http://www.intactvascular.com/clinical-trials/current-clinical-trials/ for more information on Intact Vascular’s robust clinical development program in the endovascular treatment of peripheral arterial disease and critical limb ischemia.

READ MORE:  intactvascular.com

 

RESOURCES

1Shammas, NW, Torey, JT, Shammas, WJ, et al. Intravascular Ultrasound Assessment and Correlation With Angiographic Findings Demonstrating Femoropopliteal Arterial Dissections Post Atherectomy: Results From the iDissection Study. J Invas Cardio 2018; 30:240-244.

2Bosiers M, Scheinert D, Hendricks JMH et al. Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty. J Vasc Surg 2016;64:109-16.

 

 

Previous post

26,000-PERSON STUDY: FISH OIL AND VITAMIN D PILLS NO GUARD AGAINST CANCER OR SERIOUS HEART TROUBLE

Next post

SUPERFICIAL THROMBOPHLEBITIS IN PREGNANCY: PRACTICE CHALLENGES WITH NO ENTIRELY COMPLETE GUIDELINES

Larry Storer

Larry Storer

Larry Storer has been editor of Vein Therapy News for 10 years. He has edited computer, shelter and medical publications at Publications & Communications LP for 30 years. He was also a corporate vice president and editorial director before retiring. Larry graduated from Baylor University with a BA in journalism and an MA in communications; and from Lamar University with a MED in school administration. He taught beginning and advanced reporting, beginning and advanced editing and editorial writing at Baylor University. Larry was a reporter, and city and news editor of the Beaumont Journal, and opinion editor at the Beaumont Enterprise and Beaumont Enterprise-Journal. He was also the founding managing editor of the Yuba City (California) Daily Independent-Herald.